Online inquiry

IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12977MR)

This product GTTS-WQ12977MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12977MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7139MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ2918MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ15444MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ4216MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ3413MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ2423MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ3044MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ14156MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aIL6R88
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW